-
Product Insights
Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) - Drugs In Development, 2023’, provides an overview of the Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Fred Weber’s Maryland Heights Plant
Fred Weber~s Maryland Heights Plant is a biopower project located in Missouri, United States. The project is owned by Ameren Corp and was developed by Green Companies Inc. The project came online in 2012. Empower your strategies with our Fred Weber~s Maryland Heights Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and...
-
Company Insights
Innovation and Patenting activity of Weber Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Weber Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cannabidiol in Epileptic Encephalopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cannabidiol in Epileptic Encephalopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cannabidiol in Epileptic Encephalopathy Drug Details: Cannabidiol (Epidiolex , Epidyolex) is a...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sirolimus in Benign Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sirolimus in Benign Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sirolimus in Benign Tumor Drug Details: Sirolimus (Rapamun, Rapamune, Rapalimus) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cannabidiol in Opium (Opioid) Addiction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cannabidiol in Opium (Opioid) Addiction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cannabidiol in Opium (Opioid) Addiction Drug Details: Cannabidiol (Epidiolex , Epidyolex)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ofev in Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ofev in Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ofev in Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VAD-044 in Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.VAD-044 in Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease)Drug Details:VAD-044 is under development for the treatment of hereditary...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Everolimus in Papillary Thyroid Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Everolimus in Papillary Thyroid Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Papillary Thyroid Cancer Drug Details: Everolimus (Afinitor, Votubia, RAD001)...